<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Prostate Cancer Management Algorithm</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/css/all.min.css">
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            color: #333;
            line-height: 1.6;
        }

        .header {
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            padding: 20px;
            text-align: center;
            box-shadow: 0 4px 20px rgba(0,0,0,0.1);
            position: relative;
            z-index: 100;
        }

        .header h1 {
            color: #2c3e50;
            font-size: 2.2rem;
            margin-bottom: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            gap: 15px;
        }

        .header p {
            color: #7f8c8d;
            font-size: 1.1rem;
            max-width: 800px;
            margin: 0 auto;
        }

        .container {
            display: flex;
            max-width: 1400px;
            margin: 0 auto;
            padding: 20px;
            gap: 20px;
        }

        .progress-sidebar {
            width: 280px;
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            border-radius: 15px;
            padding: 20px;
            box-shadow: 0 8px 32px rgba(0,0,0,0.1);
            position: sticky;
            top: 20px;
            height: fit-content;
            max-height: calc(100vh - 40px);
            overflow-y: auto;
        }

        .progress-title {
            font-size: 1.2rem;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .progress-item {
            display: flex;
            align-items: center;
            padding: 12px;
            margin-bottom: 10px;
            border-radius: 10px;
            cursor: pointer;
            transition: all 0.3s ease;
            border-left: 4px solid transparent;
        }

        .progress-item:hover {
            background: rgba(102, 126, 234, 0.1);
            transform: translateX(5px);
        }

        .progress-item.active {
            background: linear-gradient(135deg, #667eea, #764ba2);
            color: white;
            border-left-color: #2c3e50;
        }

        .progress-icon {
            width: 40px;
            height: 40px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 12px;
            font-size: 1.2rem;
            transition: all 0.3s ease;
        }

        .progress-item.active .progress-icon {
            transform: scale(1.1);
            box-shadow: 0 4px 15px rgba(0,0,0,0.2);
        }

        .progress-text {
            flex: 1;
        }

        .progress-label {
            font-weight: 600;
            display: block;
        }

        .progress-desc {
            font-size: 0.85rem;
            opacity: 0.8;
        }

        .main-content {
            flex: 1;
        }

        .card {
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            border-radius: 20px;
            margin-bottom: 20px;
            box-shadow: 0 8px 32px rgba(0,0,0,0.1);
            overflow: hidden;
            transition: all 0.4s cubic-bezier(0.25, 0.8, 0.25, 1);
            border: 1px solid rgba(255,255,255,0.2);
        }

        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 12px 40px rgba(0,0,0,0.15);
        }

        .card-header {
            padding: 25px;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: space-between;
            transition: all 0.3s ease;
            position: relative;
            overflow: hidden;
        }

        .card-header::before {
            content: '';
            position: absolute;
            top: 0;
            left: -100%;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255,255,255,0.3), transparent);
            transition: left 0.5s;
        }

        .card-header:hover::before {
            left: 100%;
        }

        .card-icon {
            width: 60px;
            height: 60px;
            border-radius: 15px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.8rem;
            margin-right: 20px;
            transition: all 0.3s ease;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }

        .card-header:hover .card-icon {
            transform: scale(1.1) rotate(5deg);
        }

        .card-title-section {
            flex: 1;
        }

        .card-title {
            font-size: 1.4rem;
            font-weight: 700;
            margin-bottom: 5px;
        }

        .card-subtitle {
            font-size: 0.95rem;
            opacity: 0.8;
        }

        .expand-icon {
            font-size: 1.5rem;
            transition: all 0.3s ease;
            color: rgba(0,0,0,0.4);
        }

        .card.expanded .expand-icon {
            transform: rotate(180deg);
        }

        .card-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.4s cubic-bezier(0.25, 0.8, 0.25, 1);
        }

        .card.expanded .card-content {
            max-height: 2000px;
        }

        .card-body {
            padding: 0 25px 25px;
        }

        .severity-badge {
            position: absolute;
            top: 15px;
            right: 15px;
            padding: 5px 12px;
            border-radius: 20px;
            font-size: 0.75rem;
            font-weight: 700;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.15);
        }

        .badge-red {
            background: linear-gradient(135deg, #ff6b6b, #ee5a52);
            color: white;
        }

        .badge-amber {
            background: linear-gradient(135deg, #ffd93d, #ffb347);
            color: #333;
        }

        .badge-green {
            background: linear-gradient(135deg, #6bcf7f, #4cd964);
            color: white;
        }

        .content-section {
            margin-bottom: 25px;
            padding: 20px;
            background: rgba(255,255,255,0.6);
            border-radius: 12px;
            border-left: 4px solid;
        }

        .section-title {
            font-size: 1.1rem;
            font-weight: 600;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .risk-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 15px;
        }

        .risk-card {
            padding: 15px;
            border-radius: 10px;
            background: rgba(255,255,255,0.8);
            transition: all 0.3s ease;
            border: 2px solid transparent;
        }

        .risk-card:hover {
            transform: translateY(-3px);
            border-color: currentColor;
        }

        .risk-title {
            font-weight: 600;
            margin-bottom: 8px;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .risk-criteria {
            font-size: 0.85rem;
            color: #555;
        }

        .treatment-options {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 15px;
            margin-top: 15px;
        }

        .treatment-card {
            padding: 20px;
            border-radius: 12px;
            background: rgba(255,255,255,0.8);
            transition: all 0.3s ease;
            border: 2px solid transparent;
        }

        .treatment-card:hover {
            transform: translateY(-3px);
            border-color: #667eea;
        }

        .treatment-header {
            display: flex;
            align-items: center;
            gap: 10px;
            margin-bottom: 10px;
        }

        .treatment-title {
            font-weight: 600;
            font-size: 1rem;
        }

        .treatment-description {
            font-size: 0.85rem;
            color: #555;
            margin-bottom: 10px;
        }

        .treatment-indications {
            font-size: 0.8rem;
            color: #777;
            font-style: italic;
        }

        .follow-up-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 15px;
            margin-top: 15px;
        }

        .follow-up-item {
            padding: 15px;
            border-radius: 10px;
            background: rgba(255,255,255,0.8);
            text-align: center;
            transition: all 0.3s ease;
        }

        .follow-up-item:hover {
            transform: translateY(-3px);
            background: rgba(255,255,255,1);
        }

        .follow-up-icon {
            font-size: 1.5rem;
            margin-bottom: 8px;
        }

        .follow-up-title {
            font-weight: 600;
            font-size: 0.9rem;
            margin-bottom: 5px;
        }

        .follow-up-frequency {
            font-size: 0.8rem;
            color: #666;
        }

        .complications-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 15px;
            margin-top: 15px;
        }

        .complication-item {
            padding: 15px;
            border-radius: 10px;
            background: rgba(255,255,255,0.8);
            transition: all 0.3s ease;
            border-left: 4px solid;
        }

        .complication-title {
            font-weight: 600;
            margin-bottom: 5px;
        }

        .complication-description {
            font-size: 0.85rem;
            color: #555;
        }

        .complication-likelihood {
            font-size: 0.75rem;
            color: #777;
            margin-top: 5px;
            font-weight: 600;
        }

        .timeline {
            position: relative;
            padding-left: 30px;
        }

        .timeline::before {
            content: '';
            position: absolute;
            left: 15px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: linear-gradient(to bottom, #667eea, #764ba2);
        }

        .timeline-item {
            position: relative;
            margin-bottom: 20px;
            padding: 15px;
            background: rgba(255,255,255,0.8);
            border-radius: 10px;
            margin-left: 15px;
        }

        .timeline-item::before {
            content: '';
            position: absolute;
            left: -23px;
            top: 20px;
            width: 12px;
            height: 12px;
            border-radius: 50%;
            background: #667eea;
            border: 3px solid white;
            box-shadow: 0 0 0 3px #667eea;
        }

        .timeline-title {
            font-weight: 600;
            margin-bottom: 5px;
        }

        .timeline-content {
            font-size: 0.85rem;
            color: #555;
        }

        .alert-box {
            padding: 15px;
            border-radius: 10px;
            margin: 15px 0;
            display: flex;
            align-items: flex-start;
            gap: 10px;
        }

        .alert-icon {
            font-size: 1.2rem;
            margin-top: 2px;
        }

        .alert-content {
            flex: 1;
        }

        .alert-title {
            font-weight: 600;
            margin-bottom: 5px;
        }

        .alert-text {
            font-size: 0.85rem;
        }

        .alert-red {
            background: linear-gradient(135deg, #ff6b6b20, #ee5a5220);
            border: 1px solid #ff6b6b;
            color: #c92a2a;
        }

        .alert-amber {
            background: linear-gradient(135deg, #ffd93d20, #ffb34720);
            border: 1px solid #ffd93d;
            color: #e67700;
        }

        .alert-green {
            background: linear-gradient(135deg, #6bcf7f20, #4cd96420);
            border: 1px solid #6bcf7f;
            color: #2b8a3e;
        }

        .icon-red { background: linear-gradient(135deg, #ff6b6b, #ee5a52); color: white; }
        .icon-amber { background: linear-gradient(135deg, #ffd93d, #ffb347); color: #333; }
        .icon-green { background: linear-gradient(135deg, #6bcf7f, #4cd964); color: white; }
        .icon-blue { background: linear-gradient(135deg, #4dabf7, #339af0); color: white; }
        .icon-purple { background: linear-gradient(135deg, #9775fa, #845ef7); color: white; }

        .border-red { border-color: #ff6b6b; }
        .border-amber { border-color: #ffd93d; }
        .border-green { border-color: #6bcf7f; }
        .border-blue { border-color: #4dabf7; }
        .border-purple { border-color: #9775fa; }

        @media (max-width: 768px) {
            .container {
                flex-direction: column;
            }
            
            .progress-sidebar {
                width: 100%;
                position: static;
                max-height: none;
            }
            
            .card-header {
                flex-direction: column;
                text-align: center;
                gap: 15px;
            }
            
            .card-icon {
                margin-right: 0;
            }
            
            .severity-badge {
                position: static;
                margin-top: 10px;
            }
        }

        .fade-in {
            animation: fadeIn 0.6s ease-out;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .pulse {
            animation: pulse 2s infinite;
        }

        @keyframes pulse {
            0% { box-shadow: 0 0 0 0 rgba(102, 126, 234, 0.7); }
            70% { box-shadow: 0 0 0 10px rgba(102, 126, 234, 0); }
            100% { box-shadow: 0 0 0 0 rgba(102, 126, 234, 0); }
        }

        .scroll-indicator {
            position: fixed;
            bottom: 20px;
            right: 20px;
            width: 50px;
            height: 50px;
            background: linear-gradient(135deg, #667eea, #764ba2);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            cursor: pointer;
            box-shadow: 0 4px 15px rgba(0,0,0,0.2);
            transition: all 0.3s ease;
            opacity: 0;
            transform: translateY(20px);
        }

        .scroll-indicator.visible {
            opacity: 1;
            transform: translateY(0);
        }

        .scroll-indicator:hover {
            transform: scale(1.1);
        }
    </style>
</head>
<body>
    <div class="header fade-in">
        <h1><i class="fas fa-user-md"></i> Prostate Cancer Management Algorithm</h1>
        <p>Evidence-based clinical decision support tool following BMJ Best Practice guidelines (October 2024)</p>
    </div>

    <div class="container">
        <div class="progress-sidebar fade-in">
            <div class="progress-title">
                <i class="fas fa-route"></i> Clinical Pathway
            </div>
            <div class="progress-item active" data-card="assessment">
                <div class="progress-icon icon-blue">
                    <i class="fas fa-clipboard-check"></i>
                </div>
                <div class="progress-text">
                    <span class="progress-label">Assessment</span>
                    <span class="progress-desc">Initial evaluation & risk stratification</span>
                </div>
            </div>
            <div class="progress-item" data-card="diagnosis">
                <div class="progress-icon icon-purple">
                    <i class="fas fa-microscope"></i>
                </div>
                <div class="progress-text">
                    <span class="progress-label">Diagnosis</span>
                    <span class="progress-desc">Confirmatory testing & staging</span>
                </div>
            </div>
            <div class="progress-item" data-card="treatment">
                <div class="progress-icon icon-red">
                    <i class="fas fa-syringe"></i>
                </div>
                <div class="progress-text">
                    <span class="progress-label">Treatment</span>
                    <span class="progress-desc">Risk-based management</span>
                </div>
            </div>
            <div class="progress-item" data-card="followup">
                <div class="progress-icon icon-green">
                    <i class="fas fa-chart-line"></i>
                </div>
                <div class="progress-text">
                    <span class="progress-label">Follow-up</span>
                    <span class="progress-desc">Monitoring & complications</span>
                </div>
            </div>
        </div>

        <div class="main-content">
            <!-- Assessment Card -->
            <div class="card fade-in pulse" id="assessment-card">
                <div class="card-header" onclick="toggleCard('assessment')">
                    <div class="severity-badge badge-blue">Initial</div>
                    <div class="card-icon icon-blue">
                        <i class="fas fa-clipboard-check"></i>
                    </div>
                    <div class="card-title-section">
                        <div class="card-title">Assessment & Initial Evaluation</div>
                        <div class="card-subtitle">Screening, risk factors, and clinical presentation</div>
                    </div>
                    <div class="expand-icon">
                        <i class="fas fa-chevron-down"></i>
                    </div>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="content-section border-blue">
                            <div class="section-title">
                                <i class="fas fa-search"></i> Screening Recommendations
                            </div>
                            <div class="alert-box alert-blue">
                                <div class="alert-icon"><i class="fas fa-info-circle"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Shared Decision Making</div>
                                    <div class="alert-text">PSA screening is controversial. Discuss risks/benefits with patients aged 55-69 years. Higher-risk patients (Black ancestry, family history, BRCA mutations) may start at age 40-45.</div>
                                </div>
                            </div>
                            <ul style="list-style: none; padding: 0;">
                                <li style="margin: 10px 0;"><i class="fas fa-check-circle" style="color: #4cd964; margin-right: 10px;"></i> Average risk: Discuss screening at age 50-55</li>
                                <li style="margin: 10px 0;"><i class="fas fa-exclamation-triangle" style="color: #ffd93d; margin-right: 10px;"></i> High risk: Start screening at age 40-45 (BRCA2 carriers, strong family history)</li>
                                <li style="margin: 10px 0;"><i class="fas fa-user-friends" style="color: #4dabf7; margin-right: 10px;"></i> Life expectancy ≥10 years for screening to be beneficial</li>
                            </ul>
                        </div>

                        <div class="content-section border-amber">
                            <div class="section-title">
                                <i class="fas fa-clipboard-list"></i> Key Diagnostic Factors
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-calendar-alt" style="color: #ffd93d;"></i> Age
                                    </div>
                                    <div class="risk-criteria">
                                        Most common in men >50 years. Median age at diagnosis: 68 years
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-users" style="color: #ff6b6b;"></i> Ethnicity
                                    </div>
                                    <div class="risk-criteria">
                                        Highest incidence in Black men (194.8 per 100,000) - 2x higher than white men
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-dna" style="color: #9775fa;"></i> Family History
                                    </div>
                                    <div class="risk-criteria">
                                        2.48x increased risk with one first-degree relative. 4.39x with two or more relatives
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-green">
                            <div class="section-title">
                                <i class="fas fa-stethoscope"></i> Clinical Presentation
                            </div>
                            <div class="timeline">
                                <div class="timeline-item">
                                    <div class="timeline-title">Asymptomatic (Most Common)</div>
                                    <div class="timeline-content">Detected through PSA screening ± DRE</div>
                                </div>
                                <div class="timeline-item">
                                    <div class="timeline-title">Urinary Symptoms</div>
                                    <div class="timeline-content">Nocturia, frequency, hesitancy, weak stream (more common in advanced disease or BPH)</div>
                                </div>
                                <div class="timeline-item">
                                    <div class="timeline-title">Systemic Symptoms</div>
                                    <div class="timeline-content">Weight loss, bone pain, lethargy (metastatic disease)</div>
                                </div>
                                <div class="timeline-item">
                                    <div class="timeline-title">Digital Rectal Exam</div>
                                    <div class="timeline-content">Asymmetric, indurated, or nodular prostate suggests cancer</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-red">
                            <div class="section-title">
                                <i class="fas fa-exclamation-circle"></i> Red Flags - Immediate Referral
                            </div>
                            <div class="alert-box alert-red">
                                <div class="alert-icon"><i class="fas fa-ambulance"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Suspected Metastatic Disease</div>
                                    <div class="alert-text">Bone pain, neurological symptoms, unexplained weight loss, or markedly elevated PSA (>20 ng/mL)</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Diagnosis Card -->
            <div class="card fade-in" id="diagnosis-card">
                <div class="card-header" onclick="toggleCard('diagnosis')">
                    <div class="severity-badge badge-purple">Confirmatory</div>
                    <div class="card-icon icon-purple">
                        <i class="fas fa-microscope"></i>
                    </div>
                    <div class="card-title-section">
                        <div class="card-title">Diagnosis & Risk Stratification</div>
                        <div class="card-subtitle">PSA interpretation, imaging, biopsy, and staging</div>
                    </div>
                    <div class="expand-icon">
                        <i class="fas fa-chevron-down"></i>
                    </div>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="content-section border-blue">
                            <div class="section-title">
                                <i class="fas fa-chart-line"></i> PSA Interpretation
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-check-circle" style="color: #4cd964;"></i> Normal Range
                                    </div>
                                    <div class="risk-criteria">
                                        <strong>Men ≥60 years:</strong> PSA <1 ng/mL = very low risk
                                        <br><strong>Men ≥75 years:</strong> PSA <3 ng/mL = very low risk
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-exclamation-triangle" style="color: #ffd93d;"></i> Elevated PSA
                                    </div>
                                    <div class="risk-criteria">
                                        PSA >3 ng/mL with suspicious DRE → consider biopsy
                                        <br>PSA density >0.15 ng/mL/g → increased risk
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-ruler" style="color: #4dabf7;"></i> PSA Velocity
                                    </div>
                                    <div class="risk-criteria">
                                        Increase >0.75 ng/mL/year may indicate cancer even if PSA in "normal" range
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-purple">
                            <div class="section-title">
                                <i class="fas fa-image"></i> Imaging & Biopsy
                            </div>
                            <div class="timeline">
                                <div class="timeline-item">
                                    <div class="timeline-title">Multiparametric MRI</div>
                                    <div class="timeline-content">Recommended before biopsy to identify significant lesions (PI-RADS scoring)</div>
                                </div>
                                <div class="timeline-item">
                                    <div class="timeline-title">Prostate Biopsy</div>
                                    <div class="timeline-content">Systematic ± MRI-targeted biopsy required for diagnosis and Gleason grading</div>
                                </div>
                                <div class="timeline-item">
                                    <div class="timeline-title">Staging Imaging</div>
                                    <div class="timeline-content">PSMA-PET/CT or bone scan/CT for high-risk disease (PSA >20, Gleason ≥8, T3-4)</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-red">
                            <div class="section-title">
                                <i class="fas fa-layer-group"></i> Risk Stratification (NCCN)
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card" style="border-color: #4cd964;">
                                    <div class="risk-title">
                                        <i class="fas fa-check-circle" style="color: #4cd964;"></i> Very Low Risk
                                    </div>
                                    <div class="risk-criteria">
                                        <strong>Must have ALL:</strong><br>
                                        • cT1c<br>
                                        • Gleason ≤6<br>
                                        • PSA <10 ng/mL<br>
                                        • <3 cores positive, ≤50% per core<br>
                                        • PSA density <0.15
                                    </div>
                                </div>
                                <div class="risk-card" style="border-color: #ffd93d;">
                                    <div class="risk-title">
                                        <i class="fas fa-exclamation-triangle" style="color: #ffd93d;"></i> Low Risk
                                    </div>
                                    <div class="risk-criteria">
                                        • cT1-T2a<br>
                                        • Gleason ≤6<br>
                                        • PSA <10 ng/mL
                                    </div>
                                </div>
                                <div class="risk-card" style="border-color: #ff6b6b;">
                                    <div class="risk-title">
                                        <i class="fas fa-exclamation-circle" style="color: #ff6b6b;"></i> High Risk
                                    </div>
                                    <div class="risk-criteria">
                                        • cT3-4 OR<br>
                                        • Gleason 8-10 OR<br>
                                        • PSA >20 ng/mL
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-amber">
                            <div class="section-title">
                                <i class="fas fa-dna"></i> Germline Testing
                            </div>
                            <div class="alert-box alert-amber">
                                <div class="alert-icon"><i class="fas fa-gene"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Indications for Genetic Testing</div>
                                    <div class="alert-text">Offer to patients with: metastatic/regional disease, high/very-high risk localized disease, strong family history, or known pathogenic variants (BRCA1/2, ATM, CHEK2, etc.)</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Treatment Card -->
            <div class="card fade-in" id="treatment-card">
                <div class="card-header" onclick="toggleCard('treatment')">
                    <div class="severity-badge badge-red">Management</div>
                    <div class="card-icon icon-red">
                        <i class="fas fa-syringe"></i>
                    </div>
                    <div class="card-title-section">
                        <div class="card-title">Treatment Options</div>
                        <div class="card-subtitle">Risk-based management strategies</div>
                    </div>
                    <div class="expand-icon">
                        <i class="fas fa-chevron-down"></i>
                    </div>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="content-section border-green">
                            <div class="section-title">
                                <i class="fas fa-eye"></i> Observation & Active Surveillance
                            </div>
                            <div class="alert-box alert-green">
                                <div class="alert-icon"><i class="fas fa-clock"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">When to Consider</div>
                                    <div class="alert-text">Very low-risk or low-risk disease with life expectancy <10 years OR patient preference to avoid treatment side effects</div>
                                </div>
                            </div>
                            <div class="follow-up-grid">
                                <div class="follow-up-item">
                                    <div class="follow-up-icon"><i class="fas fa-calendar-check"></i></div>
                                    <div class="follow-up-title">Observation</div>
                                    <div class="follow-up-frequency">History & DRE every 12 months<br>No biopsies</div>
                                </div>
                                <div class="follow-up-item">
                                    <div class="follow-up-icon"><i class="fas fa-microscope"></i></div>
                                    <div class="follow-up-title">Active Surveillance</div>
                                    <div class="follow-up-frequency">PSA every 6 months<br>DRE every 12 months<br>Biopsy every 2-5 years</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-blue">
                            <div class="section-title">
                                <i class="fas fa-radiation"></i> Radiotherapy Options
                            </div>
                            <div class="treatment-options">
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-bullseye" style="color: #4dabf7;"></i>
                                        <div class="treatment-title">External Beam Radiotherapy (EBRT)</div>
                                    </div>
                                    <div class="treatment-description">
                                        Definitive treatment for localized disease. Moderate hypofractionation preferred (shorter treatment course)
                                    </div>
                                    <div class="treatment-indications">
                                        <strong>Indications:</strong> Low-risk to high-risk disease
                                    </div>
                                </div>
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-seedling" style="color: #6bcf7f;"></i>
                                        <div class="treatment-title">Brachytherapy</div>
                                    </div>
                                    <div class="treatment-description">
                                        Permanent seed implant (low-dose rate) or temporary HDR. Boost to EBRT for intermediate-high risk
                                    </div>
                                    <div class="treatment-indications">
                                        <strong>Indications:</strong> Low-risk to high-risk disease (as monotherapy or boost)
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-purple">
                            <div class="section-title">
                                <i class="fas fa-cut"></i> Surgical Options
                            </div>
                            <div class="treatment-options">
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-cut" style="color: #9775fa;"></i>
                                        <div class="treatment-title">Radical Prostatectomy</div>
                                    </div>
                                    <div class="treatment-description">
                                        Surgical removal of prostate + seminal vesicles. Open, laparoscopic, or robotic approaches
                                    </div>
                                    <div class="treatment-indications">
                                        <strong>Indications:</strong> Localized disease, life expectancy ≥10 years, good performance status
                                    </div>
                                </div>
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-network-wired" style="color: #ffd93d;"></i>
                                        <div class="treatment-title">Pelvic Lymph Node Dissection</div>
                                    </div>
                                    <div class="treatment-description">
                                        Performed with radical prostatectomy based on nomogram risk of nodal involvement
                                    </div>
                                    <div class="treatment-indications">
                                        <strong>Indications:</strong> Intermediate to high-risk disease
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-red">
                            <div class="section-title">
                                <i class="fas fa-pills"></i> Androgen Deprivation Therapy (ADT)
                            </div>
                            <div class="alert-box alert-red">
                                <div class="alert-icon"><i class="fas fa-exclamation-triangle"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Timing & Duration</div>
                                    <div class="alert-text">4-6 months for intermediate-risk; 1.5-3 years for high-risk when combined with radiotherapy</div>
                                </div>
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-syringe" style="color: #ff6b6b;"></i> LHRH Agonists
                                    </div>
                                    <div class="risk-criteria">
                                        Leuprorelin, goserelin, triptorelin<br>
                                        <small>Combine with anti-androgen for first 7 days to prevent flare</small>
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-shield-alt" style="color: #ffd93d;"></i> LHRH Antagonists
                                    </div>
                                    <div class="risk-criteria">
                                        Degarelix, relugolix<br>
                                        <small>No flare phenomenon; suitable for metastatic disease</small>
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-prescription-bottle" style="color: #9775fa;"></i> Anti-androgens
                                    </div>
                                    <div class="risk-criteria">
                                        Bicalutamide, nilutamide, apalutamide, enzalutamide<br>
                                        <small>Second-generation agents for metastatic disease</small>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-amber">
                            <div class="section-title">
                                <i class="fas fa-layer-group"></i> Treatment by Risk Category
                            </div>
                            <div class="treatment-options">
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-check-circle" style="color: #4cd964;"></i>
                                        <div class="treatment-title">Very Low Risk</div>
                                    </div>
                                    <div class="treatment-description">Life expectancy <10 years: Observation<br>Life expectancy ≥10 years: Active surveillance</div>
                                </div>
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-exclamation-triangle" style="color: #ffd93d;"></i>
                                        <div class="treatment-title">Intermediate Risk</div>
                                    </div>
                                    <div class="treatment-description">Active surveillance OR EBRT ± brachytherapy ± ADT (4-6 months) OR radical prostatectomy</div>
                                </div>
                                <div class="treatment-card">
                                    <div class="treatment-header">
                                        <i class="fas fa-exclamation-circle" style="color: #ff6b6b;"></i>
                                        <div class="treatment-title">High/Very High Risk</div>
                                    </div>
                                    <div class="treatment-description">EBRT + brachytherapy boost + ADT (1.5-3 years) ± abiraterone OR radical prostatectomy + PLND</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-red">
                            <div class="section-title">
                                <i class="fas fa-globe"></i> Metastatic Disease
                            </div>
                            <div class="alert-box alert-red">
                                <div class="alert-icon"><i class="fas fa-flask"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">First-line Therapy</div>
                                    <div class="alert-text">ADT + docetaxel + abiraterone/apalutamide/darolutamide/enzalutamide (triplet therapy) OR ADT + one second-generation agent (doublet)</div>
                                </div>
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-pills" style="color: #ff6b6b;"></i> Castration-Resistant
                                    </div>
                                    <div class="risk-criteria">
                                        Continue ADT + additional agents based on biomarkers and prior therapies
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-bullseye" style="color: #4dabf7;"></i> Oligometastatic
                                    </div>
                                    <div class="risk-criteria">
                                        Consider metastasis-directed SBRT in addition to systemic therapy
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Follow-up Card -->
            <div class="card fade-in" id="followup-card">
                <div class="card-header" onclick="toggleCard('followup')">
                    <div class="severity-badge badge-green">Long-term</div>
                    <div class="card-icon icon-green">
                        <i class="fas fa-chart-line"></i>
                    </div>
                    <div class="card-title-section">
                        <div class="card-title">Follow-up & Monitoring</div>
                        <div class="card-subtitle">Surveillance, complications, and prognosis</div>
                    </div>
                    <div class="expand-icon">
                        <i class="fas fa-chevron-down"></i>
                    </div>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="content-section border-blue">
                            <div class="section-title">
                                <i class="fas fa-calendar-alt"></i> Surveillance Schedule
                            </div>
                            <div class="follow-up-grid">
                                <div class="follow-up-item">
                                    <div class="follow-up-icon"><i class="fas fa-vial"></i></div>
                                    <div class="follow-up-title">PSA Monitoring</div>
                                    <div class="follow-up-frequency">Every 6-12 months for 5 years, then annually</div>
                                </div>
                                <div class="follow-up-item">
                                    <div class="follow-up-icon"><i class="fas fa-hand-paper"></i></div>
                                    <div class="follow-up-title">DRE</div>
                                    <div class="follow-up-frequency">Consider if recurrence suspected</div>
                                </div>
                                <div class="follow-up-item">
                                    <div class="follow-up-icon"><i class="fas fa-image"></i></div>
                                    <div class="follow-up-title">Imaging</div>
                                    <div class="follow-up-frequency">For symptoms or rising PSA</div>
                                </div>
                                <div class="follow-up-item">
                                    <div class="follow-up-icon"><i class="fas fa-stethoscope"></i></div>
                                    <div class="follow-up-title">Clinical Review</div>
                                    <div class="follow-up-frequency">Every 12 months minimum</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-red">
                            <div class="section-title">
                                <i class="fas fa-exclamation-triangle"></i> PSA Recurrence
                            </div>
                            <div class="alert-box alert-red">
                                <div class="alert-icon"><i class="fas fa-radiation"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Post-Radiotherapy Failure</div>
                                    <div class="alert-text">PSA increase ≥2 ng/mL above nadir = biochemical recurrence</div>
                                </div>
                            </div>
                            <div class="alert-box alert-amber">
                                <div class="alert-icon"><i class="fas fa-cut"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Post-Prostatectomy Failure</div>
                                    <div class="alert-text">PSA persistence (not undetectable) or recurrence (detectable PSA >0.1 ng/mL on two measurements)</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-amber">
                            <div class="section-title">
                                <i class="fas fa-chart-line"></i> PSA Doubling Time (PSADT)
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-hourglass-half" style="color: #4cd964;"></i> PSADT >10 months
                                    </div>
                                    <div class="risk-criteria">
                                        Consider monitoring or secondary hormone therapy
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-hourglass-end" style="color: #ff6b6b;"></i> PSADT ≤10 months
                                    </div>
                                    <div class="risk-criteria">
                                        High risk for metastases - consider adding second-generation anti-androgen
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-purple">
                            <div class="section-title">
                                <i class="fas fa-procedures"></i> Common Complications
                            </div>
                            <div class="complications-list">
                                <div class="complication-item border-blue">
                                    <div class="complication-title">
                                        <i class="fas fa-urine" style="color: #4dabf7;"></i> Urinary Dysfunction
                                    </div>
                                    <div class="complication-description">
                                        Incontinence, urgency, frequency (more common after surgery/radiotherapy)
                                    </div>
                                    <div class="complication-likelihood">Likelihood: High</div>
                                </div>
                                <div class="complication-item border-red">
                                    <div class="complication-title">
                                        <i class="fas fa-fire" style="color: #ff6b6b;"></i> Hot Flushes
                                    </div>
                                    <div class="complication-description">
                                        From ADT - can be managed with paroxetine or clonidine
                                    </div>
                                    <div class="complication-likelihood">Likelihood: High</div>
                                </div>
                                <div class="complication-item border-red">
                                    <div class="complication-title">
                                        <i class="fas fa-bone" style="color: #ffd93d;"></i> Bone Loss
                                    </div>
                                    <div class="complication-description">
                                        ADT causes rapid BMD loss - assess FRAX score, consider bisphosphonates
                                    </div>
                                    <div class="complication-likelihood">Likelihood: High</div>
                                </div>
                                <div class="complication-item border-blue">
                                    <div class="complication-title">
                                        <i class="fas fa-egg" style="color: #4dabf7;"></i> Erectile Dysfunction
                                    </div>
                                    <div class="complication-description">
                                        Common after surgery or radiotherapy - consider PDE5 inhibitors or penile rehabilitation
                                    </div>
                                    <div class="complication-likelihood">Likelihood: High</div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-green">
                            <div class="section-title">
                                <i class="fas fa-chart-pie"></i> Prognosis
                            </div>
                            <div class="alert-box alert-green">
                                <div class="alert-icon"><i class="fas fa-percentage"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">5-Year Relative Survival Rates</div>
                                    <div class="alert-text">
                                        <strong>Localized:</strong> 100% | <strong>Regional:</strong> 100% | <strong>Distant:</strong> 38%
                                    </div>
                                </div>
                            </div>
                            <div class="risk-grid">
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-dna" style="color: #9775fa;"></i> Gleason Score
                                    </div>
                                    <div class="risk-criteria">
                                        Gleason 2-4: Low cancer mortality (6 deaths/1000 person-years)
                                        <br>Gleason 8-10: High mortality (121 deaths/1000 person-years)
                                    </div>
                                </div>
                                <div class="risk-card">
                                    <div class="risk-title">
                                        <i class="fas fa-shield-virus" style="color: #4cd964;"></i> BRCA Mutations
                                    </div>
                                    <div class="risk-criteria">
                                        BRCA2 carriers: More aggressive disease, poor survival
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section border-blue">
                            <div class="section-title">
                                <i class="fas fa-ambulance"></i> When to Refer
                            </div>
                            <div class="alert-box alert-red">
                                <div class="alert-icon"><i class="fas fa-hospital"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Urgent Referral</div>
                                    <div class="alert-text">Suspected metastatic disease, urinary retention, or significant symptoms</div>
                                </div>
                            </div>
                            <div class="alert-box alert-amber">
                                <div class="alert-icon"><i class="fas fa-user-md"></i></div>
                                <div class="alert-content">
                                    <div class="alert-title">Routine Referral</div>
                                    <div class="alert-text">Elevated PSA with suspicious DRE or MRI findings requiring biopsy/treatment planning</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <div class="scroll-indicator" id="scrollIndicator" onclick="scrollToTop()">
        <i class="fas fa-arrow-up"></i>
    </div>

    <script>
        // Card toggle functionality
        function toggleCard(cardId) {
            const card = document.getElementById(cardId + '-card');
            const isExpanded = card.classList.contains('expanded');
            
            // Close all other cards
            document.querySelectorAll('.card').forEach(c => {
                if (c !== card) {
                    c.classList.remove('expanded');
                }
            });
            
            // Toggle current card
            card.classList.toggle('expanded');
            
            // Update progress indicator
            updateProgress(cardId);
            
            // Smooth scroll to card
            setTimeout(() => {
                card.scrollIntoView({ behavior: 'smooth', block: 'nearest' });
            }, 100);
        }

        // Progress indicator functionality
        function updateProgress(activeCardId) {
            document.querySelectorAll('.progress-item').forEach(item => {
                item.classList.remove('active');
                if (item.dataset.card === activeCardId) {
                    item.classList.add('active');
                }
            });
        }

        // Progress item click handler
        document.querySelectorAll('.progress-item').forEach(item => {
            item.addEventListener('click', () => {
                const cardId = item.dataset.card;
                const card = document.getElementById(cardId + '-card');
                
                // Expand the card and scroll to it
                document.querySelectorAll('.card').forEach(c => c.classList.remove('expanded'));
                card.classList.add('expanded');
                updateProgress(cardId);
                
                setTimeout(() => {
                    card.scrollIntoView({ behavior: 'smooth', block: 'start' });
                }, 100);
            });
        });

        // Scroll to top functionality
        function scrollToTop() {
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }

        // Show/hide scroll indicator
        window.addEventListener('scroll', () => {
            const scrollIndicator = document.getElementById('scrollIndicator');
            if (window.scrollY > 300) {
                scrollIndicator.classList.add('visible');
            } else {
                scrollIndicator.classList.remove('visible');
            }
        });

        // Add fade-in animation on scroll
        const observerOptions = {
            threshold: 0.1,
            rootMargin: '0px 0px -50px 0px'
        };

        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    entry.target.classList.add('fade-in');
                }
            });
        }, observerOptions);

        // Observe all cards
        document.querySelectorAll('.card').forEach(card => {
            observer.observe(card);
        });

        // Auto-expand first card on load
        window.addEventListener('load', () => {
            setTimeout(() => {
                document.getElementById('assessment-card').classList.add('expanded');
            }, 500);
        });

        // Add smooth transitions for hover effects
        document.querySelectorAll('.risk-card, .treatment-card, .follow-up-item, .complication-item').forEach(card => {
            card.addEventListener('mouseenter', () => {
                card.style.transform = 'translateY(-5px)';
            });
            
            card.addEventListener('mouseleave', () => {
                card.style.transform = 'translateY(0)';
            });
        });

        // Keyboard navigation
        document.addEventListener('keydown', (e) => {
            if (e.key === 'ArrowDown' || e.key === 'ArrowRight') {
                const activeCard = document.querySelector('.card.expanded');
                const allCards = Array.from(document.querySelectorAll('.card'));
                const currentIndex = allCards.indexOf(activeCard);
                const nextIndex = (currentIndex + 1) % allCards.length;
                
                allCards.forEach(c => c.classList.remove('expanded'));
                allCards[nextIndex].classList.add('expanded');
                allCards[nextIndex].scrollIntoView({ behavior: 'smooth', block: 'start' });
                
                const nextCardId = allCards[nextIndex].id.replace('-card', '');
                updateProgress(nextCardId);
            } else if (e.key === 'ArrowUp' || e.key === 'ArrowLeft') {
                const activeCard = document.querySelector('.card.expanded');
                const allCards = Array.from(document.querySelectorAll('.card'));
                const currentIndex = allCards.indexOf(activeCard);
                const prevIndex = (currentIndex - 1 + allCards.length) % allCards.length;
                
                allCards.forEach(c => c.classList.remove('expanded'));
                allCards[prevIndex].classList.add('expanded');
                allCards[prevIndex].scrollIntoView({ behavior: 'smooth', block: 'start' });
                
                const prevCardId = allCards[prevIndex].id.replace('-card', '');
                updateProgress(prevCardId);
            }
        });

        // Add pulse animation to severity badges for urgent items
        setInterval(() => {
            document.querySelectorAll('.badge-red').forEach(badge => {
                badge.classList.add('pulse');
                setTimeout(() => badge.classList.remove('pulse'), 2000);
            });
        }, 10000);
    </script>
</body>
</html>